Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced a significant collaboration with Modulant Biosciences LLC. The two companies have signed a binding term sheet that grants Modulant exclusive global rights to develop and commercialize EL-22, a pioneering probiotic approach aimed at muscle preservation in livestock. This strategic partnership allows Northstrive to monetize its intellectual property in the animal health sector. If successfully developed and brought to market, EL-22 could become a long-term revenue-generating asset. The agreement also outlines that Modulant will share a portion of revenues from sublicensing and commercial activities with Northstrive, with specified royalty rates. The parties plan to finalize the definitive licensing agreement in the coming months, pending necessary approvals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。